The U.S. Food and Drug Administration (FDA) granted initial approval to rimegepant (Nurtec ODT) on February 27, 2020. This approval designates rimegepant as a Type 1 - New Molecular Entity, marking a significant addition to available treatments.
Background
Rimegepant is sponsored by Pfizer. Its classification as a Type 1 - New Molecular Entity indicates that it contains an active ingredient that has not been previously approved by the FDA, representing a novel therapeutic agent. This designation highlights the significant research and development investment made by the sponsor to bring an innovative compound to market.
What this means
The initial FDA approval of rimegepant as a New Molecular Entity signifies the introduction of a novel treatment option into the therapeutic landscape. This classification means the active ingredient, rimegepant, is entirely new to the market, representing a distinct chemical structure and potentially a new mechanism of action compared to existing therapies. For clinicians, this approval expands the available tools for patient management, offering a new agent that has undergone comprehensive regulatory review for safety and efficacy. Researchers will gain a new compound to study, potentially leading to further insights into its therapeutic class or broader applications. Patient advocates can highlight this new approval as an additional choice for individuals seeking treatment. The designation as a Type 1 - New Molecular Entity underscores the rigorous development and evaluation process required to bring such an innovative drug to market, establishing its foundational role in clinical practice.
Source
The information regarding this initial FDA approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for Nurtec ODT (rimegepant sulfate) (NDA 212728) was documented on February 27, 2020, on accessdata.fda.gov.